PRQR
$6.60
Proqr Therapeutics
($.23)
(3.37%)
PRQR
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.25)
Revenue:  $1.40 Mil
Thursday
Feb 3
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PRQR reports earnings?
Beat
Meet
Miss

Where is PRQR's stock price going from here?
Up
Flat
Down
Stock chart of PRQR
Analysts
Summary of analysts' recommendations for PRQR
Score
Grade
Pivots
Resistance
$7.23
$7.03
$6.82

$6.62

Support
$6.41
$6.21
$6.00
Tweet
Growth
Description
ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.